Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Regeneron Pharmaceuticals ( REGN)

Stock return since Jan. 1: 84%

I was on the fence about including Regeneron on this list until the stock strolled past $100 per share Monday. I get it -- Regeneron has a newly approved and launched eye drug, Eylea, that's requires fewer inconvenient, uncomfortable (creepy?) eye injections than Roche's Lucentis (and repurposed, off-label Avastin) for treating age-related macular degeneration. But Regeneron is now valued at well over $9 billion. Even if Eylea does really well and brings in $1 billion in sales (not a sure thing by any means), Regeneron's valuation is bubblicious. Regeneron is the new Vertex Pharmaceuticals ( VRTX).

Regeneron shares closed Tuesday down less than 1% to $100.34.

If you liked this article you might like

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Cytori Therapeutics Stock Sliding on Offering Price Discount

GNC Plummets, Mallinckrodt Regains Ground Ahead of Market's Open

Insider Trading Alert - SUNE, NRIM And CYTX Traded By Insiders